Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients (EVOLVE)

Clinical Trial ID NCT02028442

PubWeight™ 5.96‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02028442

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology 2014 1.22
2 Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses. Mol Ther Methods Clin Dev 2016 0.86
3 Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther 2015 0.83
4 Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics 2015 0.77
5 Promising oncolytic agents for metastatic breast cancer treatment. Oncolytic Virother 2015 0.76
6 Oncolytic virotherapy for urological cancers. Nat Rev Urol 2016 0.76
7 Virotherapy: cancer gene therapy at last? F1000Res 2016 0.75
Next 100